Startup profile · funding coverage
Neurava funding, valuation and investors
Baltimore medtech building wearable monitoring for epilepsy seizures and SUDEP risk stratification.
Keep track of Neurava
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · Baltimore, MD
Overview
Neurava develops multimodal wearable technology to detect seizures, cardiorespiratory dysfunction, and stratify Sudden Unexpected Death in Epilepsy (SUDEP) risk. Baltimore-based Neurava received a $4M NIH Blueprint MedTech Optimizer award in April 2026 (grant 3U54EB033650-04S5) to develop and validate a quantitative SUDEP risk platform toward first-in-human trials. The company has raised prior venture funding reported above $2M in addition to non-dilutive awards.
Why Neurava is interesting
Wearable epilepsy stack with a $4M NIH Blueprint MedTech Optimizer award (Apr 2026) to build a first-in-class SUDEP risk algorithm — Baltimore HQ at 101 W Dickman St, grant-plus-equity path typical of Hopkins-adjacent device startups.
Product & use cases
Wearable epilepsy monitoring with seizure detection and SUDEP risk stratification roadmap.
- Home and clinical seizure alerting
- SUDEP risk quantification for neurologists and families
- Epilepsy management planning with objective physiologic data
Key facts
- HQ Baltimore, MD (101 W Dickman St)
- NIH Blueprint Optimizer (Apr 2026): $4M for SUDEP risk algorithm
- Multimodal wearable for seizure and cardiorespiratory monitoring
- Prior venture funding $2M+ reported; MedTech Innovator finalist (2023)
Funding history (newest first)
Grant (NIH Blueprint)
2026-04 $4M- NIH Blueprint MedTech (lead)
Competitive landscape
Edge: NIH-selected neurotech on mortality outcomes — competes on clinical evidence bar, not consumer wellness UX alone.
-
Empatica direct
Wearable seizure detection incumbent.
-
Manual seizure diaries incumbent
Default workflow; no continuous monitoring.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Neurava's financing or category context.
FAQs about Neurava
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.